TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Cipla Ltd ( (IN:CIPLA) ) is now available.
Cipla Ltd has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the processing of dematerialization requests for the quarter ending September 30, 2025. This announcement underscores Cipla’s compliance with regulatory requirements, ensuring that its securities are properly managed and listed on the relevant stock exchanges, thereby maintaining transparency and trust with its stakeholders.
More about Cipla Ltd
Cipla Ltd is a leading pharmaceutical company based in India, known for its extensive range of pharmaceutical products and services. The company focuses on the development and manufacturing of medicines to treat respiratory, cardiovascular, and other chronic diseases, making significant contributions to the healthcare industry.
Average Trading Volume: 51,685
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1274.5B INR
For an in-depth examination of CIPLA stock, go to TipRanks’ Overview page.